icnst-2018-scientifictracks-abstracts

11 / 15

Page 24
Notes:
alliedacademies
Materials Science and Nanotechnology | Volume 2
May 21-22, 2018 | New York, USA
International Conference on
Nanoscience & Technology
Current cancer treatment modalities include surgery,
chemotherapy, radiotherapy, and hormone therapy.
Unfortunately, none of these approaches is sufficient on
its own due to non-specificity and inadequate efficacy.
Nanotechnology offers necessary tools which aim to
ensure optimal delivery of the desired drug to the target
tissue with minimal off-target toxicity to adjacent tissues.
Radiotherapy in combination with nanotechnology offers
a potentially unique anti-cancer approach. We used
Actinium-225, an α particle emitting radionuclide with a 10d
half-life and a yield of 4 α particles in its decay chain. Our
nanoparticles, cDOTs, are tumor-selective, ultrasmall Cy5
containing, poly(ethylene glycol)-coated silica constructs
functionalized with melanoma-targeting peptides. They
were approved for a first-in-human clinical trial in 2011
for melanoma patients. To enhance cDOTs specificity and
improve oncological use, we conjugated cDOTS to an α
melanocyte-stimulating hormone (αMSH)-modified ligand.
MSH is an endogenous peptide hormone and neuropeptide
of the melanocortin family. First we confirmed the uptake of
these cDOTs by B16/F10 melanoma cell line using imaging
and FACS. The complete uptake was observed after 72h.
We performed a biodistribution study of [225Ac]cDOTs-MSH
in naïve and tumor bearing mice. Moreover, we evaluated
the maximum tolerated dose (MTD) in melanoma tumors
bearing mice. Four doses were tested, 0, 625, 1250 and 2500
nCi and a dose of 625 nCi was determined to be the MTD.
A radiotherapy treatment study using melanoma tumor in
immune competent mice was conducted using a dose of
300 nCi. The overall survival was improved in specific and
non-specific treatment groups compared to vehicle group.
In addition, the tumor size was significantly reduced in
specific group when compared to a vehicle group after 30
days of treatment. We also evaluated the changes in T cell
and macrophage infiltrates in tumor bearing mice and repot
that the greatest infiltration was observed after 96h post
treatment.
Speaker Biography
Aleksandra M. Urbanska has completed her PhD from the Department of Biomedical
Engineering summa cum laude, Faculty of Medicine at McGill University in Montreal,
Canada. She was trained as a postdoctoral fellow at Massachusetts Institute of
Technology under supervision of prof. Robert S. Langer as well as at Columbia University
Medical Center where she applied her multidisciplinary skills in nanotechnology, stem
cells, tissue engineering, biomaterials and drug delivery. She has over 40 publications
that have been cited over 800 times. Currently she is a fellow researcher at Memorial
Sloan Kettering Cancer Center in New York City.
e:
Treating Melanoma with [225Ac]cdots nanoparticles
Aleksandra M Urbanska
Memorial Sloan Kettering Cancer Centre, USA